Business Roundtable chief to replace Tauzin at PhRMA

Share this article:
John Castellani
John Castellani
PhRMA named Business Roundtable chief John Castellani as its president and CEO, tapping a longtime trade association hand to replace former Congressional kingpin Billy Tauzin.

Castellani has headed the Business Roundtable for nine years. The group, a coalition of big business CEOs, was actively involved in the healthcare reform debate, and like PhRMA, was largely supportive of the White House and Congressional Democrats.

His appointment suggests that PhRMA members were looking for a consensus-builder rather than a general.

“It sounds like a safe choice,” said John Kamp, executive director of the Coalition for Healthcare Communication. “He's very well-known in the business community. But this is not a pharma person that knows the business. He's more likely to be staff than a leader.”

Tauzin, an inveterate legislative wheeler-dealer and master strategist, announced he was stepping down from the role in February, just as prospects for healthcare reform legislation, once seemingly-inevitable, were looking shaky. His strategy of supporting reform and making substantial concessions for leverage in crafting the legislation had angered some industry hard-liners, though he had some powerful backers such as Pfizer's Jeff Kindler and AstraZeneca's David Brennan, the incoming and current PhRMA board chairs (the chairmanship is a one-year position rotated between the chiefs of major PhRMA member companies).

In a statement, Brennan hailed Castellani's “exceptional policy-making experience and integrity” and said “his experience in coalition building and strong reputation of working across the political divide set him apart.”

A Brennan lieutenant, senior AstraZeneca PR exec Chip Davis, was seconded over to PhRMA in April to lead day-to-day operations and coordinate between Brennan and the search committee until a new president and CEO was named.

Dolly Judge, a former top lobbyist at Pfizer and Roche and head of Hill & Knowlton's healthcare practice, called Castellani “a great pick.”

“He works across the aisles, can go deep on issues, and believes in the industry fundamentally,” said Judge.

Before joining Business Roundtable, Castellani held senior posts at auto parts giant Tenneco Inc., National Association of Manufacturers and automotive and aerospace firm TRW. He began his career as an environmental scientist at General Electric.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...